aldo-keto reductase family 1 member C5, pseudogeneGenealiases: []
Q-omics provides the consensus-scored AKR1C5P profile across patient tissues and cancer cell-line models. AKR1C5P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, AKR1C5P is differentially expressed in 7, with the highest sampling consensus in BRCA. Additionally, AKR1C5P RNA expression shows 9,512 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight STAD, BRCA, and LSCC as cancer lineages where AKR1C5P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AKR1C5P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AKR1C5P survival associations across molecular data types. AKR1C5P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AKR1C5P RNA expression–survival associations across cancer types. High AKR1C5P expression shows unfavorable associations in STAD, UVM, KICH and UCEC, but favorable associations in UCS and MESO. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify STAD as the clearest survival context for AKR1C5P RNA expression.
This table summarizes AKR1C5P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for AKR1C5P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AKR1C5P shows lower tumor expression in BRCA and CHOL and higher tumor expression in HNSC, KIRC, BLCA and KIRP. The BRCA box plot shows higher AKR1C5P RNA expression in normal versus tumor tissue (log2 FC = −0.180, t-test p = .004).
This table shows molecular features associated with AKR1C5P in patient tissues and cancer cell lines. In patient samples, AKR1C5P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
